LEPR and obesity disorder: This synthetic peptide was approved by FDA at the end of 2020 for treating obesity caused by genetic defects in pro-opiomelanocortin (POMC), leptin receptor (LEPR), or proprotein convertase subtilisin/kexin type 1 (PCSK1) [219].